MBX Biosciences Management
Management criteria checks 0/4
MBX Biosciences' CEO is Peter Hawryluk, appointed in Jan 2020, has a tenure of 5.75 years. total yearly compensation is $4.86M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 2.63% of the company’s shares, worth $16.35M. The average tenure of the management team and the board of directors is 1.6 years and 2.8 years respectively.
Key information
Peter Hawryluk
Chief executive officer
US$4.9m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 5yrs |
| CEO ownership | 2.6% |
| Management average tenure | 1.6yrs |
| Board average tenure | 2.8yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$55m |
| Jun 30 2024 | n/a | n/a | -US$47m |
| Mar 31 2024 | n/a | n/a | -US$39m |
| Dec 31 2023 | US$5m | US$420k | -US$33m |
Compensation vs Market: Peter's total compensation ($USD4.86M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Insufficient data to compare Peter's compensation with company performance.
CEO
Peter Hawryluk (55 yo)
5yrs
Tenure
US$4,862,064
Compensation
Mr. P. Kent Hawryluk, MBA, served as Chief Business Officer of Avidity Biosciences LLC from January 2013 to December 19, 2019. Mr. Hawryluk is a Partner at Twilight Venture Partners, LLC. He co-founded and...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5yrs | US$4.86m | 2.63% $ 16.4m | |
| Chief Financial Officer | 2.8yrs | US$1.05m | 0% $ 0 | |
| Chief Scientific Officer | 1.5yrs | no data | no data | |
| Vice President of Marketing | 1.7yrs | no data | no data | |
| Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.6yrs
Average Tenure
57yo
Average Age
Experienced Management: MBX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.8yrs | US$4.86m | 2.63% $ 16.4m | |
| Independent Director | 4.5yrs | no data | no data | |
| Independent Director | 4.5yrs | no data | no data | |
| Independent Director | 4.3yrs | no data | 0.31% $ 1.9m | |
| Independent Director | 4.5yrs | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.8yrs | no data | 0.050% $ 309.2k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 2.2yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
2.8yrs
Average Tenure
64yo
Average Age
Experienced Board: MBX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 07:54 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MBX Biosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seamus Fernandez | Guggenheim Securities, LLC |
| Michael Yee | Jefferies LLC |
| Jessica Fye | J.P. Morgan |